Triglyceride-Lowering Therapies Reduce Cardiovascular Disease Event Risk in Subjects with Hypertriglyceridemia

Kevin C. Maki,Michael Davidson,John R. Guyton,Carl E. Orringer,Ian Hamilton‐Craig,Dominik D. Alexander

Journal of Clinical Lipidology（2015）

引用 0|浏览0

暂无评分

摘要

Dr. Maki has received research grant support and consulting fees from AstraZeneca, as well as GlaxoSmithKline, AbbVie, Matinas Biopharma, Amarin, and Trygg Pharmaceuticals. This study was funded by AstraZeneca.

查看译文

关键词

hypertriglyceridemia,cardiovascular disease,triglyceride-lowering

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要